Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022

Rhea-AI Summary

Cara Therapeutics, Inc. (Nasdaq: CARA) will host a conference call on November 7, 2022, at 4:30 p.m. ET to discuss third quarter 2022 financial results and provide a corporate update. The company is known for its innovative KORSUVA® (difelikefalin) injection, the first FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in hemodialysis patients. Cara is also developing an oral version of difelikefalin and has initiated Phase 3 programs for pruritus in non-dialysis dependent advanced chronic kidney disease and atopic dermatitis.

Positive

• First FDA-approved treatment for moderate-to-severe pruritus in hemodialysis patients.
• Developing an oral formulation of difelikefalin.
• Initiated Phase 3 programs for pruritus in advanced chronic kidney disease and atopic dermatitis.

Negative

• None.

STAMFORD, Conn., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, November 7, 2022, at 4:30 p.m. ET to report third quarter 2022 financial results and provide a corporate update.

To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN.

A live audio webcast and archived replay of the call will be available under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA^® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. A Phase 2 proof-of-concept trial in primary biliary cholangitis patients with moderate-to-severe pruritus is ongoing. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com

FAQ

When will Cara Therapeutics report its third quarter 2022 financial results?

Cara Therapeutics will report its third quarter 2022 financial results on November 7, 2022, at 4:30 p.m. ET.

What is KORSUVA® and its significance for Cara Therapeutics?

KORSUVA® (difelikefalin) is the first FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.

What new developments is Cara Therapeutics pursuing?

Cara is developing an oral formulation of difelikefalin and has initiated Phase 3 trials for treating pruritus in non-dialysis dependent advanced chronic kidney disease and atopic dermatitis.